Effects of Semaglutide and Tirzepatide on Recurrent Weight Gain After Bariatric Surgery: A Systematic Review and Meta-analysis
- 28.11.2025
- Review
- Verfasst von
- Angel Alois Osorio Manyari
- Azucena Lirio Armas Alvarez
- Joel Davis Osorio Manyari
- Francisco Onieva Gonzalez
- Sjaak Pouwels
- Erschienen in
- Obesity Surgery | Ausgabe 12/2025
Abstract
Fifteen to forty% of patients experience recurrent weight gain (RWG) after metabolic bariatric surgery (MBS). Glucagon-like peptide receptor agonists (GLP-1 RAs) are effective treatments for obesity in nonsurgical patients. To assess the effects of semaglutide and tirzepatide after MBS, we conducted a meta-analysis of data from inception to August 2025. Eight retrospective studies and 964 patients were included. The percentage total weight loss (%TWL) was − 10.97% [95% CI, − 13.41 to − 8.53; p < 0.05] for semaglutide and − 13.63% [95% CI, − 22.59 to − 4.67; p < 0.05] for tirzepatide. The evidence suggests that semaglutide and tirzepatide result in weight reduction in patients with RWG after MBS.
Anzeige
- Titel
- Effects of Semaglutide and Tirzepatide on Recurrent Weight Gain After Bariatric Surgery: A Systematic Review and Meta-analysis
- Verfasst von
-
Angel Alois Osorio Manyari
Azucena Lirio Armas Alvarez
Joel Davis Osorio Manyari
Francisco Onieva Gonzalez
Sjaak Pouwels
- Publikationsdatum
- 28.11.2025
- Verlag
- Springer US
- Erschienen in
-
Obesity Surgery / Ausgabe 12/2025
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428 - DOI
- https://doi.org/10.1007/s11695-025-08414-2
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.